News | October 03, 2024
CCI approves acquisition of Bharat Serums and Vaccines by Mankind Pharma
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
The acquisition is based on an enterprise value of Rs. 1,660 crore
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Subscribe To Our Newsletter & Stay Updated
